Insider · CIK 0001609805

Nussbaum Ran

Reports to the SEC for 9 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001609805

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-03	LBRXLB PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2025-09-12	LBRXLB PHARMACEUTICALS INCC Conversion	Director	CConversion	+412K sh	—	—	411,681
2025-09-12	LBRXLB PHARMACEUTICALS INCP Purchase	Director	PPurchase	+1M sh	$15.00	+$15M	1,411,681
2025-09-12	LBRXLB PHARMACEUTICALS INC · Series C Preferred StockC Conversion	Director	CConversion	−10M sh	—	—	0
2025-09-10	LBRXLB PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+22.4K sh	—	—	22,449
2025-06-04	KROSKeros Therapeutics, Inc.A Award	Director, 10% Owner	AAward	+5,250 sh	—	—	5,250
2025-06-04	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+10.5K sh	—	—	10,500
2024-05-30	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+10K sh	—	—	10,000
2023-06-06	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+10K sh	—	—	10,000
2022-11-29	KROSKeros Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−3,539 sh	$0.00	−$0.354	2,284,612
2022-11-29	KROSKeros Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−1,723 sh	$0.00	−$0.172	1,121,045
2022-11-29	KROSKeros Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−1,914 sh	$0.00	−$0.191	1,226,412
2022-11-29	KROSKeros Therapeutics, Inc. · Call Options (obligation to sell)X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−3,539 sh	—	—	0
2022-11-29	KROSKeros Therapeutics, Inc. · Call Options (obligation to sell)X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−1,723 sh	—	—	0
2022-11-29	KROSKeros Therapeutics, Inc. · Call Options (obligation to sell)X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−1,914 sh	—	—	0
2022-10-21	URGNUroGen Pharma Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+48K sh	$5.94	+$285K	1,485,168
2022-10-21	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−32.7K sh	—	—	0
2022-10-21	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−15.3K sh	—	—	0
2022-10-21	URGNUroGen Pharma Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+48K sh	$5.94	+$285K	1,481,927
2022-10-21	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−32.7K sh	—	—	0
2022-10-21	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−15.3K sh	—	—	0
2022-06-16	URGNUroGen Pharma Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+2,211 sh	$5.00	+$11.1K	1,437,169
2022-06-16	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,211 sh	—	—	0
2022-06-15	ELOXEloxx Pharmaceuticals, Inc. · Stock Options (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-06-08	URGNUroGen Pharma Ltd. · Stock Option (right to buy)A Award	Director	AAward	+6,817 sh	—	—	6,817
2022-06-08	URGNUroGen Pharma Ltd. · Stock Option (right to buy)A Award	Director	AAward	+3,183 sh	—	—	3,183
2022-06-06	URGNUroGen Pharma Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+1,030 sh	$5.00	+$5,150	1,434,958
2022-06-06	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,030 sh	—	—	0
2022-06-06	URGNUroGen Pharma Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+1,030 sh	$5.00	+$5,150	1,433,928
2022-06-06	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,030 sh	—	—	0
2022-06-01	KROSKeros Therapeutics, Inc. · Stock Options (right to buy)A Award	Director, 10% Owner	AAward	+8,293 sh	—	—	8,293
2021-06-07	URGNUroGen Pharma Ltd. · Stock Option (right to buy)A Award	Director	AAward	+6,817 sh	—	—	6,817
2021-06-07	URGNUroGen Pharma Ltd. · Stock Option (right to buy)A Award	Director	AAward	+3,183 sh	—	—	3,183
2021-06-01	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+8,293 sh	—	—	8,293
2021-05-19	ELOXEloxx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2021-05-13	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+1.28M sh	$1.35	+$1.73M	1,791,470
2021-05-13	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+2.63M sh	$1.35	+$3.55M	3,679,797
2021-05-13	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+1.42M sh	$1.35	+$1.92M	1,989,551
2021-05-13	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+593K sh	$1.35	+$800K	616,592
2021-03-25	URGNUroGen Pharma Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+2,211 sh	$5.00	+$11.1K	1,433,928
2021-03-25	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,211 sh	—	—	0
2021-03-25	URGNUroGen Pharma Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+1,030 sh	$5.00	+$5,150	1,431,717
2021-03-25	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,030 sh	—	—	0
2021-03-24	URGNUroGen Pharma Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+1,030 sh	$5.00	+$5,150	1,465,199
2021-03-24	URGNUroGen Pharma Ltd. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,030 sh	—	—	0
2021-01-22	Prevail Therapeutics Inc.U Disposition from Tender	Director	UDisposition from Tender	−1.58M sh	—	—	0
2021-01-22	Prevail Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2020-11-17	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+26.6K sh	$50.00	+$1.33M	2,288,151
2020-11-17	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+13K sh	$50.00	+$648K	1,122,768
2020-11-17	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+14.4K sh	$50.00	+$720K	1,228,326

Recent filings

Accepted (ET)
Jun 54
Nussbaum Ran0001609805-26-000003
SEC(opens sec.gov)
Sep 164
Nussbaum Ran0001609805-25-000006
SEC(opens sec.gov)
Sep 124
Nussbaum Ran0001415889-25-024447
SEC(opens sec.gov)
Jun 64
Nussbaum Ran0001415889-25-015976
SEC(opens sec.gov)
Jun 34
Nussbaum Ran0001415889-24-015154
SEC(opens sec.gov)
Jun 84
Nussbaum Ran0001209191-23-035457
SEC(opens sec.gov)
Feb 284
Nussbaum Ran0001437749-23-004866
SEC(opens sec.gov)
Feb 284/A
Nussbaum Ran0001437749-23-004868
SEC(opens sec.gov)
Feb 284/A
Nussbaum Ran0001437749-23-004870
SEC(opens sec.gov)
Nov 304
Nussbaum Ran0001209191-22-059052
SEC(opens sec.gov)

Companies

Address

C/O LB PHARMACEUTICALS INC ONE PENNSYLVANIA PLAZA, SUITE 1025

NEW YORK, NY, 10119